- Home
- SUZ vs QGEN Comparison
SUZ vs QGEN Comparison
Compare SUZ & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUZ | QGEN |
|---|---|---|
| Founded | 1924 | 1986 |
| Country | Brazil | Netherlands |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 10.2B |
| IPO Year | 2002 | 1998 |
Fundamental Metrics
Financial Performance| Metric | SUZ | QGEN |
|---|---|---|
| Price | $8.30 | $36.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $45.76 |
| AVG Volume (30 Days) | ★ 3.3M | 2.0M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | 2.15% | ★ 7.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.28 | $8.18 |
| Revenue Next Year | $13.57 | $5.71 |
| P/E Ratio | ★ $5.58 | $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.92 | $32.53 |
| 52 Week High | $11.54 | $57.82 |
Technical Indicators
Market Signals| Indicator | SUZ | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 51.03 |
| Support Level | $8.11 | $32.85 |
| Resistance Level | $9.66 | $38.10 |
| Average True Range (ATR) | 0.16 | 0.89 |
| MACD | 0.07 | 0.13 |
| Stochastic Oscillator | 55.56 | 45.08 |
Price Performance
Historical ComparisonAbout SUZ Suzano S.A.
Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).